FDA Approves Humira for Pediatric Crohn’s Disease

FDA Approves Humira for Pediatric Crohn’s Disease
Abbvie reported today that the U.S. Food and Drug Administration (FDA) has approved HUMIRA® (adalimumab) as a new treatment for Crohn’s disease in children over six years of age, when other treatments have failed. HUMIRA® is the only biological drug to be approved by FDA to treat young patients with pediatric Crohn’s disease. Jeffrey S. Hyams, M.D.,

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *